Overview

A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare ofatumumab & chlorambucil (O-Chl) versus ofatumumab & bendamustine (O-B) in patients with Chronic Lymphocytic Leukaemia who are considered not fit enough for rituximab, fludarabine & cyclophosphamide (R-FC).

Phase:

Phase 3

Details

Lead Sponsor:

University of Liverpool

Collaborators:

Chugai Pharma USA
GlaxoSmithKline
Napp Pharmaceuticals Limited

Treatments:

Antibodies, Monoclonal
Bendamustine Hydrochloride
Chlorambucil
Ofatumumab